Mydecine Innovations Group Inc.
MYCOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.01 | 0.00 |
| FCF Yield | -15.54% | -696.44% | -168.08% | -3,756.91% |
| EV / EBITDA | -2.87 | -0.64 | -0.62 | -0.16 |
| Quality | ||||
| ROIC | 30.88% | 144.68% | -293.89% | -468.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.01 | 0.20 | 0.49 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -60.92% |
| Free Cash Flow Growth | 99.12% | 50.17% | 65.39% | -219.72% |
| Safety | ||||
| Net Debt / EBITDA | -2.78 | -0.57 | -0.30 | -0.13 |
| Interest Coverage | -1.71 | -7.21 | -17.23 | -107.66 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -242,604.04 | -14,511.31 | 9,981.90 |